Back to search
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations trials you may qualify forPhase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of TAS-117 in patients with advanc…